Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Cash: 2020-2024

Historic Change in Cash for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to -$20.2 million.

  • ARS Pharmaceuticals' Change in Cash rose 164.50% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year increase of 195.33%. This contributed to the annual value of -$20.2 million for FY2024, which is 85.56% up from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Change in Cash is -$20.2 million, which was up 85.56% from -$139.5 million recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Change in Cash high stood at $376.4 million for FY2020, and its period low was -$139.5 million during FY2023.
  • Moreover, its 3-year median value for Change in Cash was -$20.2 million (2024), whereas its average is -$3.1 million.
  • Per our database at Business Quant, ARS Pharmaceuticals' Change in Cash spiked by 323.32% in 2022 and then crashed by 192.75% in 2023.
  • Yearly analysis of 5 years shows ARS Pharmaceuticals' Change in Cash stood at $376.4 million in 2020, then tumbled by 90.56% to $35.5 million in 2021, then spiked by 323.32% to $150.5 million in 2022, then tumbled by 192.75% to -$139.5 million in 2023, then skyrocketed by 85.56% to -$20.2 million in 2024.